TEST:

Galleri Test

Liposomes represent a promising strategy for the safe and effective delivery of citral to control C. auris infection.

Even though inactivation of yebC2EF had no discernible impact on the physiology or virulence of E. faecalis, this may be due to functional redundancy with other translation factors such as EF-P (translation elongation factor P, EF0287) and YfmR (ABCF ATPase YfmR/Uup, EF1575). As in the related microorganisms Bacillus subtilis and Streptococcus pyogenes, these factors can compensate for the loss of YebC2.

This study reports the first case of bloodstream infection caused by P. soli confirmed by whole-genome sequencing. PS1 harbored multiple virulence‑related genetic modules and exhibited corresponding pathogenic phenotypes. These findings support that P. soli may have opportunistic pathogenic potential.

Data unveiled at this year's ASCO Annual meeting show that GRAIL's Galleri multi-cancer early detection (MCED) test failed to reduce stage III and IV cancers in the landmark NHS-Galleri trial, although there was an improvement in stage IV alone. Experts say the findings fall short of demonstrating a large enough clinical benefit for MCED testing that would warrant Galleri's implementation.

Analysis of these new data showed that the primary endpoint of the trial, aiming to reduce the incidence of stage III-IV cancer by at least 20 %, was missed. The trial is still ongoing.

''GRAIL, Inc...will present additional data from both the NHS-Galleri trial and the PATHFINDER 2 study further evaluating the Galleri® multi-cancer early detection (MCED) test at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 29-June 2, 2026.''

''GRAIL, Inc...today announced a collaboration with Epic to bring the Galleri® multi-cancer early detection test into one of the nation’s most widely used electronic health record (EHR) platforms, supporting broader adoption across health systems in the United States.''

Most patients with a cancer signal detected on a MCED test were true positives with a cancer consistent with the CSO reported. Patients had their MCED test results quickly adjudicated when presenting to a dedicated clinical program supporting a role for cancer diagnostic expertise in evaluating MCED tests.

''GRAIL, Inc...today announced topline results from the landmark, randomized, controlled NHS-Galleri trial, which evaluated annual multi-cancer screening with the Galleri® test in England’s National Health Service (NHS) over three years in 142,000 demographically representative participants aged 50 to 77. ''

Clinical utility of MCD testing for symptomatic patients in the United Kingdom varies substantially across referral pathways but is favorable for gynecologic and GI cancers. Future pathway-specific optimization of MCD tests must consider clinical utility explicitly and does not require retraining the underlying machine learning classifiers.

The MCED test correctly predicted the CSO in 87% of cases with a reported cancer type, consistent with previous clinical studies. CSO enabled efficient workup in most patients, with a median 39.5 days from result receipt to cancer diagnosis.

Additional prospective randomized clinical trials are needed before widespread adoption. The information and data included in this manuscript was previously presented as a poster (e612 Poster Q&A Sessions) at the 2024 American Society for Radiation Oncology Annual Meeting.